The DOI matches its Crossref record; 187 of the 187 references it cites were found in a registry or an index.
Idiopathic Pulmonary Fibrosis (IPF): An Overview
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterised by chronic, progressive scarring of the lungs and the pathological hallmark of usual interstitial pneumonia. Current paradigms suggest alveolar epithelial cell damage is a key initiating factor. Globally, incidence of the disease is rising, with associated high morbidity, mortality, and economic healthcare burden. Diagnosis relies on a multidisciplinary team approach with exclusion of other causes of interstitial lung disease. Over recent years, two novel antifibrotic therapies, pirfenidone and nintedanib, have been developed, providing treatment options for many patients with IPF, with several other agents in early clinical trials. Current efforts are directed at identifying key biomarkers that may direct more customized patient-centred healthcare to improve outcomes for these patients in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation
Walter, P., & Ron, D. (2011) · Science · doi:10.1126/science.1209038 · Cited by 5,924
Control of inositol 1,4,5-trisphosphate-induced Ca2+ release by cytosolic Ca2+
Bootman, M. D., Missiaen, L., Parys, J. B., De Smedt, H., & Casteels, R. (1995) · Biochemical Journal · doi:10.1042/bj3060445 · Cited by 5,120
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 2×
“Subsequently, the INPULSIS trials (INPULSIS-1 and 2) [127], parallel phase III, multicentre RCTs, demonstrated a significant reduction in the rate of FVC decline over a 52-week period, in IPF patients receiving nintedanib compared to placebo.”
MethodResultA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975 · cited 1×
“A further phase III trial, the Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis (ASCEND) study [119], was requested by the United States Food and Drug Administration (US FDA) due to discrepancies between the two CAPACITY trials in meeting their primary endpoints.”
BackgroundThe Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
THE MAMMALIAN UNFOLDED PROTEIN RESPONSE
Schröder, M., & Kaufman, R. J. (2005) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.074134 · Cited by 3,026
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056 · cited 1×
“A comprehensive review of the pathogenesis of IPF is beyond the scope of this article and has been discussed recently elsewhere [28,29].”
BackgroundThe epithelial–mesenchymal transition: new insights in signaling, development, and disease
Lee, J. M., Dedhar, S., Kalluri, R., & Thompson, E. W. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200601018 · Cited by 2,019
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Klinge, U., Park, J.-K., & Klosterhalfen, B. (2013) · Pathobiology · doi:10.1159/000348446 · Cited by 1,783
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Zhu, Z., Homer, R. J., Wang, Z., Chen, Q., Geba, G. P., Wang, J., Zhang, Y., & Elias, J. A. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5909 · Cited by 1,719
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Cellular senescence mediates fibrotic pulmonary disease
Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14532 · Cited by 1,613 · cited 1×
“Genetic deletion of specific senescent cells (p16INK4a positive) and similarly the use of pharmacological drivers of senescent cell apoptosis, improved lung function and fitness of animals in pre-clinical models of pulmonary fibrosis [68].”
BackgroundTGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357
Circulating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
A Common MUC5B Promoter Polymorphism and Pulmonary Fibrosis
Seibold, M. A., Wise, A. L., Speer, M. C., Steele, M. P., Brown, K. K., Loyd, J. E., Fingerlin, T. E., Zhang, W., Gudmundsson, G., Groshong, S. D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013660 · Cited by 1,198
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
Lynch, D. A., Sverzellati, N., Travis, W. D., Brown, K. K., Colby, T. V., Galvin, J. R., Goldin, J. G., Hansell, D. M., Inoue, Y., Johkoh, T., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30433-2 · Cited by 1,030
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
A Mutation in the Surfactant Protein C Gene Associated with Familial Interstitial Lung Disease
Nogee, L. M., Dunbar, A. E., Wert, S. E., Askin, F., Hamvas, A., & Whitsett, J. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200102223440805 · Cited by 929
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
Hutchinson, J., Fogarty, A., Hubbard, R., & McKeever, T. (2015) · European Respiratory Journal · doi:10.1183/09031936.00185114 · Cited by 913
Adult-onset pulmonary fibrosis caused by mutations in telomerase
Tsakiri, K. D., Cronkhite, J. T., Kuan, P. J., Xing, C., Raghu, G., Weissler, J. C., Rosenblatt, R. L., Shay, J. W., & Garcia, C. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701009104 · Cited by 894 · cited 2×
“Six telomere-related genes have been linked to familial pulmonary fibrosis (FPF): TERT [30], TERC [58], DKC1 [59], TINF2 [60], RTEL1 [61], and PARN [62], although TERT mutations are most frequent, occurring in approximately 15% those with affected kindreds [63].”
BackgroundPathogenesis of Idiopathic Pulmonary Fibrosis
Wolters, P. J., Collard, H. R., & Jones, K. D. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104706 · Cited by 862
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis
Fingerlin, T. E., Murphy, E., Zhang, W., Peljto, A. L., Brown, K. K., Steele, M. P., Loyd, J. E., Cosgrove, G. P., Lynch, D., Groshong, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2609 · Cited by 809
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.
Baumgartner, K. B., Samet, J. M., Stidley, C. A., Colby, T. V., & Waldron, J. A. (1997) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.155.1.9001319 · Cited by 767
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716
Telomeres, lifestyle, cancer, and aging
Shammas, M. A. (2011) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0b013e32834121b1 · Cited by 681
Thomas, A. Q., Lane, K., Phillips, J., Prince, M., Markin, C., Speer, M., Schwartz, D. A., Gaddipati, R., Marney, A., Johnson, J., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200112-123oc · Cited by 641
Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., & Ryffel, B. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.208223 · Cited by 633
Effects of cigarette smoke on the human airway epithelial cell transcriptome
Spira, A., Beane, J., Shah, V., Liu, G., Schembri, F., Yang, X., Palma, J., & Brody, J. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401422101 · Cited by 619
Noth, I., Zhang, Y., Ma, S.-F., Flores, C., Barber, M., Huang, Y., Broderick, S. M., Wade, M. S., Hysi, P., Scuirba, J., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70045-6 · Cited by 614
MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., MacDonald, S. D., Pardo, A., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050093 · Cited by 588
Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK
Gribbin, J., Hubbard, R. B., Le Jeune, I., Smith, C. J. P., West, J., & Tata, L. J. (2006) · Thorax · doi:10.1136/thx.2006.062836 · Cited by 576
Idiopathic pulmonary fibrosis: pathogenesis and management
Sgalla, G., Iovene, B., Calvello, M., Ori, M., Varone, F., & Richeldi, L. (2018) · Respiratory Research · doi:10.1186/s12931-018-0730-2 · Cited by 573
Role of Epithelial Cells in Idiopathic Pulmonary Fibrosis: From Innocent Targets to Serial Killers
Selman, M., & Pardo, A. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-003tk · Cited by 529
Regulation of Transforming Growth Factor-β1–driven Lung Fibrosis by Galectin-3
MacKinnon, A. C., Gibbons, M. A., Farnworth, S. L., Leffler, H., Nilsson, U. J., Delaine, T., Simpson, A. J., Forbes, S. J., Hirani, N., Gauldie, J., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201106-0965oc · Cited by 516
Epithelial Endoplasmic Reticulum Stress and Apoptosis in Sporadic Idiopathic Pulmonary Fibrosis
Korfei, M., Ruppert, C., Mahavadi, P., Henneke, I., Markart, P., Koch, M., Lang, G., Fink, L., Bohle, R.-M., Seeger, W., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200802-313oc · Cited by 514
Randomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401739 · Cited by 505
Kisseleva, T., & Brenner, D. A. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-190 · Cited by 503
(2007) · Clinical Atlas of Interstitial Lung Disease · doi:10.1007/978-1-84628-326-0_6 · Cited by 499
The rising incidence of idiopathic pulmonary fibrosis in the UK
Navaratnam, V., Fleming, K. M., West, J., Smith, C. J. P., Jenkins, R. G., Fogarty, A., & Hubbard, R. B. (2011) · Thorax · doi:10.1136/thx.2010.148031 · Cited by 484
Stuart, B. D., Choi, J., Zaidi, S., Xing, C., Holohan, B., Chen, R., Choi, M., Dharwadkar, P., Torres, F., Girod, C. E., et al. (2015) · Nature Genetics · doi:10.1038/ng.3278 · Cited by 469
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2015 · Cited by 468
Richeldi, L., Cottin, V., du Bois, R. M., Selman, M., Kimura, T., Bailes, Z., Schlenker-Herceg, R., Stowasser, S., & Brown, K. K. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.02.001 · Cited by 463
Peljto, A. L., Zhang, Y., Fingerlin, T. E., Ma, S.-F., Garcia, J. G. N., Richards, T. J., Silveira, L. J., Lindell, K. O., Steele, M. P., Loyd, J. E., et al. (2013) · JAMA · doi:10.1001/jama.2013.5827 · Cited by 453
Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., & Arimura, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.046 · Cited by 436
Clinical and Pathologic Features of Familial Interstitial Pneumonia
Steele, M. P., Speer, M. C., Loyd, J. E., Brown, K. K., Herron, A., Slifer, S. H., Burch, L. H., Wahidi, M. M., Phillips, J. A., Sporn, T. A., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1104oc · Cited by 432
Lawson, W. E., Crossno, P. F., Polosukhin, V. V., Roldan, J., Cheng, D.-S., Lane, K. B., Blackwell, T. R., Xu, C., Markin, C., Ware, L. B., et al. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00382.2007 · Cited by 429
MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium
Schembri, F., Sridhar, S., Perdomo, C., Gustafson, A. M., Zhang, X., Ergun, A., Lu, J., Liu, G., Zhang, X., Bowers, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806383106 · Cited by 427
Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation
Horan, G. S., Wood, S., Ona, V., Li, D. J., Lukashev, M. E., Weinreb, P. H., Simon, K. J., Hahm, K., Allaire, N. E., Rinaldi, N. J., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-805oc · Cited by 420
Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis
Chapman, H. A. (2011) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012110-142225 · Cited by 412
Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases
Ishikawa, N., Hattori, N., Yokoyama, A., & Kohno, N. (2012) · Respiratory Investigation · doi:10.1016/j.resinv.2012.02.001 · Cited by 402
Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive
Newton, C. A., Batra, K., Torrealba, J., Kozlitina, J., Glazer, C. S., Aravena, C., Meyer, K., Raghu, G., Collard, H. R., & Garcia, C. K. (2016) · European Respiratory Journal · doi:10.1183/13993003.00308-2016 · Cited by 400
OHNISHI, H., YOKOYAMA, A., KONDO, K., HAMADA, H., ABE, M., NISHIMURA, K., HIWADA, K., & KOHNO, N. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.3.2107134 · Cited by 398
Burlingham, W. J., Love, R. B., Jankowska-Gan, E., Haynes, L. D., Xu, Q., Bobadilla, J. L., Meyer, K. C., Hayney, M. S., Braun, R. K., Greenspan, D. S., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28031 · Cited by 398
Is Idiopathic Pulmonary Fibrosis an Environmental Disease?
Taskar, V. S., & Coultas, D. B. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200512-131tk · Cited by 383
Telomere Lengths, Pulmonary Fibrosis and Telomerase (TERT) Mutations
Diaz de Leon, A., Cronkhite, J. T., Katzenstein, A.-L. A., Godwin, J. D., Raghu, G., Glazer, C. S., Rosenblatt, R. L., Girod, C. E., Garrity, E. R., Xing, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010680 · Cited by 377
Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs
Lawson, W. E., Cheng, D.-S., Degryse, A. L., Tanjore, H., Polosukhin, V. V., Xu, X. C., Newcomb, D. C., Jones, B. R., Roldan, J., Lane, K. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107559108 · Cited by 363
Telomeres and age-related disease: how telomere biology informs clinical paradigms
Armanios, M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66370 · Cited by 347
Tomassetti, S., Wells, A. U., Costabel, U., Cavazza, A., Colby, T. V., Rossi, G., Sverzellati, N., Carloni, A., Carretta, E., Buccioli, M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0711oc · Cited by 337
Nathan, S. D., Albera, C., Bradford, W. Z., Costabel, U., Glaspole, I., Glassberg, M. K., Kardatzke, D. R., Daigl, M., Kirchgaessler, K.-U., Lancaster, L. H., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30326-5 · Cited by 335 · cited 1×
“In addition, there was a reduction in the relative risk of all-cause and IPF-related mortality at 52 weeks with pirfenidone treatment [121].”
BackgroundInterobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT
Walsh, S. L. F., Calandriello, L., Sverzellati, N., Wells, A. U., & Hansell, D. M. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207252 · Cited by 334
Herazo-Maya, J. D., Noth, I., Duncan, S. R., Kim, S., Ma, S.-F., Tseng, G. C., Feingold, E., Juan-Guardela, B. M., Richards, T. J., Lussier, Y., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005964 · Cited by 325
Heterogeneous Increase in CD34-positive Alveolar Capillaries in Idiopathic Pulmonary Fibrosis
Ebina, M., Shimizukawa, M., Shibata, N., Kimura, Y., Suzuki, T., Endo, M., Sasano, H., Kondo, T., & Nukiwa, T. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200308-1111oc · Cited by 320
Serum surfactant proteins‐A and ‐D as biomarkers in idiopathic pulmonary fibrosis
Greene, K. E., King, T. E., Kuroki, Y., Bucher-Bartelson, B., Hunninghake, G. W., Newman, L. S., Nagae, H., & Mason, R. J. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00081102 · Cited by 316
Jenkins, R. G., Simpson, J. K., Saini, G., Bentley, J. H., Russell, A.-M., Braybrooke, R., Molyneaux, P. L., McKeever, T. M., Wells, A. U., Flynn, A., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00048-x · Cited by 314
Herpesvirus DNA Is Consistently Detected in Lungs of Patients with Idiopathic Pulmonary Fibrosis
Tang, Y.-W., Johnson, J. E., Browning, P. J., Cruz-Gervis, R. A., Davis, A., Graham, B. S., Brigham, K. L., Oates, J. A., Loyd, J. E., & Stecenko, A. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.6.2633-2640.2003 · Cited by 311
Stuart, B. D., Lee, J. S., Kozlitina, J., Noth, I., Devine, M. S., Glazer, C. S., Torres, F., Kaza, V., Girod, C. E., Jones, K. D., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70124-9 · Cited by 310
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial
Vancheri, C., Kreuter, M., Richeldi, L., Ryerson, C. J., Valeyre, D., Grutters, J. C., Wiebe, S., Stansen, W., Quaresma, M., Stowasser, S., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1301oc · Cited by 305
van Moorsel, C. H. M., van Oosterhout, M. F. M., Barlo, N. P., de Jong, P. A., van der Vis, J. J., Ruven, H. J. T., van Es, H. W., van den Bosch, J. M. M., & Grutters, J. C. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0953oc · Cited by 294
Human Cytomegalovirus Infection Activates and Regulates the Unfolded Protein Response
Isler, J. A., Skalet, A. H., & Alwine, J. C. (2005) · Journal of Virology · doi:10.1128/jvi.79.11.6890-6899.2005 · Cited by 285
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
Costabel, U., Inoue, Y., Richeldi, L., Collard, H. R., Tschoepe, I., Stowasser, S., & Azuma, A. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0562oc · Cited by 280
Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease
Wang, Q., Usinger, W., Nichols, B., Gray, J., Xu, L., Seeley, T. W., Brenner, M., Guo, G., Zhang, W., Oliver, N., et al. (2011) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-4-4 · Cited by 278
Liu, F., Killian, J. K., Yang, M., Walker, R. L., Hong, J. A., Zhang, M., Davis, S., Zhang, Y., Hussain, M., Xi, S., et al. (2010) · Oncogene · doi:10.1038/onc.2010.129 · Cited by 273
Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF
Lawson, W. E. (2004) · Thorax · doi:10.1136/thx.2004.026336 · Cited by 272
Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis
Naikawadi, R. P., Disayabutr, S., Mallavia, B., Donne, M. L., Green, G., La, J. L., Rock, J. R., Looney, M. R., & Wolters, P. J. (2016) · JCI Insight · doi:10.1172/jci.insight.86704 · Cited by 267
TGF-β Activation and Lung Fibrosis
Tatler, A. L., & Jenkins, G. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-003aw · Cited by 263
A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model
Swaney, J., Chapman, C., Correa, L., Stebbins, K., Bundey, R., Prodanovich, P., Fagan, P., Baccei, C., Santini, A., Hutchinson, J., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00828.x · Cited by 261
Mulugeta, S., Nguyen, V., Russo, S. J., Muniswamy, M., & Beers, M. F. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0009oc · Cited by 257
Galli, J. A., Pandya, A., Vega‐Olivo, M., Dass, C., Zhao, H., & Criner, G. J. (2017) · Respirology · doi:10.1111/resp.13024 · Cited by 257
Pigment Epithelium–derived Factor in Idiopathic Pulmonary Fibrosis: A Role in Aberrant Angiogenesis
Cosgrove, G. P., Brown, K. K., Schiemann, W. P., Serls, A. E., Parr, J. E., Geraci, M. W., Schwarz, M. I., Cool, C. D., & Worthen, G. S. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200308-1151oc · Cited by 253
Intraluminal fibrosis in interstitial lung disorders.
Basset, F., Ferrans, V. J., Soler, P., Takemura, T., Fukuda, Y., & Crystal, R. G. (1986) · PubMed Central · Cited by 249
Pan, J., Li, D., Xu, Y., Zhang, J., Wang, Y., Chen, M., Lin, S., Huang, L., Chung, E. J., Citrin, D. E., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.02.216 · Cited by 242
Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis
Lee, J. S., Song, J. W., Wolters, P. J., Elicker, B. M., King, T. E., Kim, D. S., & Collard, H. R. (2012) · European Respiratory Journal · doi:10.1183/09031936.00050911 · Cited by 241
Evans, C. M., Fingerlin, T. E., Schwarz, M. I., Lynch, D., Kurche, J., Warg, L., Yang, I. V., & Schwartz, D. A. (2016) · Physiological Reviews · doi:10.1152/physrev.00004.2016 · Cited by 238
Tanjore, H., Blackwell, T. S., & Lawson, W. E. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00410.2011 · Cited by 236
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
Kolb, M., Richeldi, L., Behr, J., Maher, T. M., Tang, W., Stowasser, S., Hallmann, C., & du Bois, R. M. (2017) · Thorax · doi:10.1136/thoraxjnl-2016-208710 · Cited by 235
Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
Strongman, H., Kausar, I., & Maher, T. M. (2018) · Advances in Therapy · doi:10.1007/s12325-018-0693-1 · Cited by 233
Interaction of IL-13 and C10 in the Pathogenesis of Bleomycin-Induced Pulmonary Fibrosis
Belperio, J. A., Dy, M., Burdick, M. D., Xue, Y. Y., Li, K., Elias, J. A., & Keane, M. P. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2002-0009oc · Cited by 232
Stock, C. J., Sato, H., Fonseca, C., Banya, W. A. S., Molyneaux, P. L., Adamali, H., Russell, A.-M., Denton, C. P., Abraham, D. J., Hansell, D. M., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-201786 · Cited by 231
Maher, T. M., van der Aar, E. M., Van de Steen, O., Allamassey, L., Desrivot, J., Dupont, S., Fagard, L., Ford, P., Fieuw, A., & Wuyts, W. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30181-4 · Cited by 231
Mice with Pulmonary Fibrosis Driven by Telomere Dysfunction
Povedano, J. M., Martinez, P., Flores, J. M., Mulero, F., & Blasco, M. A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.028 · Cited by 225 · cited 1×
“In preclinical models, telomere dysfunction, studied in telomerase-deficient mice [56] or through the disruption of the shelterin complex formation in ATII cells of mice [57], both induce the formation of pulmonary fibrosis.”
BackgroundSafety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis
Ogura, T., Taniguchi, H., Azuma, A., Inoue, Y., Kondoh, Y., Hasegawa, Y., Bando, M., Abe, S., Mochizuki, Y., Chida, K., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00198013 · Cited by 215
A Variant in the Promoter of MUC5B and Idiopathic Pulmonary Fibrosis
Zhang, Y., Noth, I., Garcia, J. G. N., & Kaminski, N. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1013504 · Cited by 214
Does Chronic Microaspiration Cause Idiopathic Pulmonary Fibrosis?
Lee, J. S., Collard, H. R., Raghu, G., Sweet, M. P., Hays, S. R., Campos, G. M., Golden, J. A., & King, T. E. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.07.033 · Cited by 209
Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey
Cosgrove, G. P., Bianchi, P., Danese, S., & Lederer, D. J. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-017-0560-x · Cited by 208
Serum Amyloid P Inhibits Fibrosis Through FcγR-Dependent Monocyte-Macrophage Regulation in Vivo
Castaño, A. P., Lin, S.-L., Surowy, T., Nowlin, B. T., Turlapati, S. A., Patel, T., Singh, A., Li, S., Lupher, M. L., & Duffield, J. S. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000111 · Cited by 206
STEWART, J. P., EGAN, J. J., ROSS, A. J., KELLY, B. G., LOK, S. S., HASLETON, P. S., & WOODCOCK, A. A. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.4.9807077 · Cited by 204
Shulgina, L., Cahn, A. P., Chilvers, E. R., Parfrey, H., Clark, A. B., Wilson, E. C. F., Twentyman, O. P., Davison, A. G., Curtin, J. J., Crawford, M. B., et al. (2013) · Thorax · doi:10.1136/thoraxjnl-2012-202403 · Cited by 190
Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis
Molyneaux, P. L., Cox, M. J., Wells, A. U., Kim, H. C., Ji, W., Cookson, W. O. C., Moffatt, M. F., Kim, D. S., & Maher, T. M. (2017) · Respiratory Research · doi:10.1186/s12931-017-0511-3 · Cited by 190
Raghu, G., Lynch, D., Godwin, J. D., Webb, R., Colby, T. V., Leslie, K. O., Behr, J., Brown, K. K., Egan, J. J., Flaherty, K. R., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70011-6 · Cited by 186
Drug Treatment of Idiopathic Pulmonary Fibrosis
Canestaro, W. J., Forrester, S. H., Raghu, G., Ho, L., & Devine, B. E. (2016) · Chest · doi:10.1016/j.chest.2015.11.013 · Cited by 186
Exome Sequencing Identifies Mutant TINF2 in a Family With Pulmonary Fibrosis
Alder, J. K., Stanley, S. E., Wagner, C. L., Hamilton, M., Hanumanthu, V. S., & Armanios, M. (2015) · Chest · doi:10.1378/chest.14-1947 · Cited by 181
Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada
Hopkins, R. B., Burke, N., Fell, C., Dion, G., & Kolb, M. (2016) · European Respiratory Journal · doi:10.1183/13993003.01504-2015 · Cited by 181
White, E. S., Xia, M., Murray, S., Dyal, R., Flaherty, C. M., Flaherty, K. R., Moore, B. B., Cheng, L., Doyle, T. J., Villalba, J., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201505-0862oc · Cited by 180
Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria
Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201602-0402oc · Cited by 180
Herazo-Maya, J. D., Sun, J., Molyneaux, P. L., Li, Q., Villalba, J. A., Tzouvelekis, A., Lynn, H., Juan-Guardela, B. M., Risquez, C., Osorio, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30349-1 · Cited by 175
Chung, J. H., Chawla, A., Peljto, A. L., Cool, C. D., Groshong, S. D., Talbert, J. L., McKean, D. F., Brown, K. K., Fingerlin, T. E., Schwarz, M. I., et al. (2015) · Chest · doi:10.1378/chest.14-0976 · Cited by 175
Raghu, G., Scholand, M. B., de Andrade, J., Lancaster, L., Mageto, Y., Goldin, J., Brown, K. K., Flaherty, K. R., Wencel, M., Wanger, J., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.01030-2015 · Cited by 175
Molecular biomarkers in idiopathic pulmonary fibrosis
Ley, B., Brown, K. K., & Collard, H. R. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00014.2014 · Cited by 172
Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997–2008
Hutchinson, J. P., McKeever, T. M., Fogarty, A. W., Navaratnam, V., & Hubbard, R. B. (2016) · European Respiratory Journal · doi:10.1183/13993003.00378-2016 · Cited by 167
Albera, C., Costabel, U., Fagan, E. A., Glassberg, M. K., Gorina, E., Lancaster, L., Lederer, D. J., Nathan, S. D., Spirig, D., & Swigris, J. J. (2016) · European Respiratory Journal · doi:10.1183/13993003.01966-2015 · Cited by 166
Hughes, G., Toellner, H., Morris, H., Leonard, C., & Chaudhuri, N. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5090078 · Cited by 166
Self-citationHeterozygous RTEL1 mutations are associated with familial pulmonary fibrosis
Kannengiesser, C., Borie, R., Ménard, C., Réocreux, M., Nitschké, P., Gazal, S., Mal, H., Taillé, C., Cadranel, J., Nunes, H., et al. (2015) · European Respiratory Journal · doi:10.1183/09031936.00040115 · Cited by 162
Costabel, U., Albera, C., LANCASTER, L. H., Lin, C.-Y., Hormel, P., Hulter, H. N., & Noble, P. W. (2017) · Respiration · doi:10.1159/000479976 · Cited by 161
Izzotti, A., Calin, G. A., Steele, V. E., Croce, C. M., & De Flora, S. (2009) · The FASEB Journal · doi:10.1096/fj.09-135251 · Cited by 158
A Novel Dyskerin (DKC1) Mutation Is Associated With Familial Interstitial Pneumonia
Kropski, J. A., Mitchell, D. B., Markin, C. R., Polosukhin, V. V., Choi, L., Johnson, J. E., Lawson, W. E., Phillips, J. A., Cogan, J. D., Blackwell, T. S., et al. (2014) · CHEST Journal · doi:10.1378/chest.13-2224 · Cited by 155
Blood Biomarkers MMP-7 and SP-A
Song, J. W., Do, K., Jang, S. J., Colby, T. V., Han, S., & Kim, D. S. (2013) · CHEST Journal · doi:10.1378/chest.11-2735 · Cited by 153
Epithelial Necrosis and Alveolar Collapse in the Pathogenesis of Usual Interstitial Pneumonia
Myers, J. L., & Katzenstein, A.-L. A. (1988) · CHEST Journal · doi:10.1378/chest.94.6.1309 · Cited by 151
Blood Biomarkers in Idiopathic Pulmonary Fibrosis
Guiot, J., Moermans, C., Henket, M., Corhay, J.-L., & Louis, R. (2017) · Lung · doi:10.1007/s00408-017-9993-5 · Cited by 147
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis
Collard, H. R., Richeldi, L., Kim, D. S., Taniguchi, H., Tschoepe, I., Luisetti, M., Roman, J., Tino, G., Schlenker‐Herceg, R., Hallmann, C., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.01339-2016 · Cited by 143
Mulugeta, S., Maguire, J. A., Newitt, J. L., Russo, S. J., Kotorashvili, A., & Beers, M. F. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00025.2007 · Cited by 137
A Rearranged Form of Epstein–Barr Virus DNA Is Associated with Idiopathic Pulmonary Fibrosis
Kelly, B. G., Lok, S., Hasleton, P. S., Egan, J. J., & Stewart, J. P. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2103058 · Cited by 135
Ishii, H., Mukae, H., Kadota, J., Kaida, H., Nagata, T., Abe, K., Matsukura, S., & Kohno, S. (2003) · Thorax · doi:10.1136/thorax.58.1.52 · Cited by 135
Validation of the prognostic value of MMP‐7 in idiopathic pulmonary fibrosis
Tzouvelekis, A., Herazo‐Maya, J. D., Slade, M., Chu, J., Deiuliis, G., Ryu, C., Li, Q., Sakamoto, K., Ibarra, G., Pan, H., et al. (2017) · Respirology · doi:10.1111/resp.12920 · Cited by 130
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
Diamantopoulos, A., Wright, E., Vlahopoulou, K., Cornic, L., Schoof, N., & Maher, T. M. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0631-8 · Cited by 122
MUC5B and Idiopathic Pulmonary Fibrosis
Yang, I. V., Fingerlin, T. E., Evans, C. M., Schwarz, M. I., & Schwartz, D. A. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201503-110aw · Cited by 120
Murray, L. A., Zhang, H., Oak, S. R., Coelho, A. L., Herath, A., Flaherty, K. R., Lee, J. S., Bell, M., Knight, D. A., Martínez, F. J., et al. (2014) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0342oc · Cited by 119
Buro-Auriemma, L. J., Salit, J., Hackett, N. R., Walters, M. S., Strulovici‐Barel, Y., Staudt, M. R., Fuller, J. A., Mahmoud, M., Stevenson, C. S., Hilton, H., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt326 · Cited by 117
Crossno, P. F., Polosukhin, V. V., Blackwell, T. S., Johnson, J. E., Markin, C. R., Moore, P. E., Worrell, J. A., Stahlman, M. T., Phillips, J. A., Loyd, J. E., et al. (2010) · CHEST Journal · doi:10.1378/chest.09-0790 · Cited by 115
Characterization of the innate immune response to chronic aspiration in a novel rodent model
Appel, J. Z., Lee, S. M., Hartwig, M. G., Li, B., Hsieh, C.-C., Cantu, E., Yoon, Y., Lin, S. S., Parker, W., & Davis, R. D. (2007) · Respiratory Research · doi:10.1186/1465-9921-8-87 · Cited by 111
CRYPTOGENIC FIBROSING ALVEOLITIS AND EPSTEIN-BARR VIRUS: AN ASSOCIATION?
Vergnon, J., de Thé, G., Weynants, P., Vincent, M., Mornex, J., & Brune, J. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90702-5 · Cited by 110
van den Blink, B., Dillingh, M. R., Ginns, L. C., Morrison, L. D., Moerland, M., Wijsenbeek, M. S., Trehu, E., Bartholmai, B. J., & Burggraaf, J. (2016) · European Respiratory Journal · doi:10.1183/13993003.00850-2015 · Cited by 102
Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis
Dillingh, M. R., van den Blink, B., Moerland, M., van Dongen, M. G. J., Levi, M. M., KleinJan, A., Wijsenbeek, M. S., Lupher, M., Harper, D. M., Getsy, J. A., et al. (2013) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2013.01.008 · Cited by 100
Marshall, D. C., Salciccioli, J. D., Shea, B. S., & Akuthota, P. (2018) · European Respiratory Journal · doi:10.1183/13993003.01603-2017 · Cited by 100
Th-17, Monokines, Collagen Type V, and Primary Graft Dysfunction in Lung Transplantation
Bobadilla, J. L., Love, R. B., Jankowska−Gan, E., Xu, Q., Haynes, L. D., Braun, R. K., Hayney, M. S., del Río, A. M., Meyer, K. C., Greenspan, D. S., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200612-1901oc · Cited by 96
The role of telomeres and telomerase in the pathology of human cancer and aging
Shin, J., Hong, A., Solomon, M. J., & Lee, C. S. (2006) · Pathology · doi:10.1080/00313020600580468 · Cited by 81
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Brunnemer, E., Wälscher, J., Ehlers-Tenenbaum, S., Hausmanns, J., Schulze, K., Seiter, M., Heußel, C. P., Warth, A., Herth, F. J. F., & Kreuter, M. (2018) · Respiration · doi:10.1159/000485933 · Cited by 81
Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities
Ho, J. E., Gao, W. D., Levy, D. A., Santhanakrishnan, R., Araki, T., Rosas, I. O., Hatabu, H., Latourelle, J. C., Nishino, M., Dupuis, J., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201509-1753oc · Cited by 79
Vittal, R., Mickler, E. A., Fisher, A. J., Zhang, C., Rothhaar, K., Gu, H., Brown, K. M., Emtiazdjoo, A., Lott, J. M., Frye, S. B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076451 · Cited by 78
Kaneko, M., Inoue, H., Nakazawa, R., Azuma, N., Suzuki, M., Yamauchi, S., Margolin, S. B., Tsubota, K., & Saito, I. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00618.x · Cited by 77
Oikonomidi, S., Κostikas, Κ., Tsilioni, I., Tanou, K., Gourgoulianis, K. I., & Kiropoulos, T. S. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787846587 · Cited by 77
Bonella, F., Kreuter, M., Hagmeyer, L., Neurohr, C., Keller, C., Kohlhaeufl, M. J., Müller–Quernheim, J., Milger, K., & Prasse, A. (2016) · Respiration · doi:10.1159/000448288 · Cited by 73
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis
Brownell, R., Kaminski, N., Woodruff, P. G., Bradford, W. Z., Richeldi, L., Martínez, F. J., & Collard, H. R. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201601-0169ci · Cited by 71
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
Wilkes, D. S., Chew, T., Flaherty, K. R., Frye, S. B., Gibson, K. F., Kaminski, N., Klemsz, M. J., Lange, W., Noth, I., & Rothhaar, K. (2015) · European Respiratory Journal · doi:10.1183/09031936.00105314 · Cited by 67
PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery
Maher, T. M. (2013) · European Respiratory Review · doi:10.1183/09059180.00000913 · Cited by 67
Lin, C., Borensztajn, K., & Spek, C. A. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13623 · Cited by 66
Maden, C. H., Fairman, D., Chalker, M., Costa, M. J., Fahy, W. A., Garman, N., Lukey, P. T., Mant, T., Parry, S., Simpson, J. K., et al. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2435-3 · Cited by 66
Tzouvelekis, A., Karampitsakos, Τ., Kontou, M., GRANITSAS, A. N., Malliou, I., Anagnostopoulos, A., Ntolios, P., Tzilas, V., Bouros, E., Steiropoulos, P., et al. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.01.006 · Cited by 66
Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis
Guiot, J., Bondue, B., Henket, M., Corhay, J. L., & Louis, R. E. (2016) · BMC Pulmonary Medicine · doi:10.1186/s12890-016-0249-6 · Cited by 64
Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis
Fidler, L. M., Sitzer, N., Shapera, S., & Shah, P. S. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.03.008 · Cited by 62
Rabeyrin, M., Thivolet, F., Ferretti, G., Chalabreysse, L., Jankowski, A., Cottin, V., Pison, C. M., Cordier, J.-F., & Lantuéjoul, S. (2015) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2015.05.003 · Cited by 59
Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis
Loveman, E., Copley, V. R., Scott, D. A., Colquitt, J. L., Clegg, A. J., & O’Reilly, K. M. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0034-y · Cited by 59
Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty
Cottin, V. (2016) · European Respiratory Journal · doi:10.1183/13993003.01633-2016 · Cited by 56
Kaunisto, J., Kelloniemi, K., Sutinen, E., Hodgson, U., Piilonen, A. K., Kaarteenaho, R. L., Mäkitaro, R., Purokivi, M., Lappi‐Blanco, E., Saarelainen, S. K., et al. (2015) · BMC Pulmonary Medicine · doi:10.1186/s12890-015-0074-3 · Cited by 55
Autotaxin Emerges as a Therapeutic Target for Idiopathic Pulmonary Fibrosis
Tager, A. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0235ed · Cited by 53
Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
Tzouvelekis, A., Karampitsakos, Τ., Ntolios, P., Tzilas, V., Bouros, E., Markozannes, E., Malliou, I., Anagnostopoulos, A., GRANITSAS, A. N., Steiropoulos, P., et al. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00213 · Cited by 49
Kropski, J. A., Lawson, W. E., & Blackwell, T. S. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00335.2011 · Cited by 46
Ohkubo, H., Nakagawa, H., & Niimi, A. (2017) · Respiratory Investigation · doi:10.1016/j.resinv.2017.10.003 · Cited by 42
Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis: A Review
Fahim, A., Crooks, M. G., & Hart, S. P. (2010) · Pulmonary Medicine · doi:10.1155/2011/634613 · Cited by 37
“Any fool can make a rule and any fool will mind it”
Wells, A. U. (2016) · BMC Medicine · doi:10.1186/s12916-016-0562-1 · Cited by 37
Manika, Κ., Alexiou‐Daniel, S., Papakosta, D., Papa, A., Kontakiotis, T., Patakas, D., & Ántoniadis, A. (2007) · PubMed · Cited by 35
Personalized Medicine: A Personal View
Meyer, U. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.238 · Cited by 35
Manguán-García, C., Pintado‐Berninches, L., Carrillo, J., Machado-Pinilla, R., Sastre, L., Pérez-Quilis, C., Esmorís, I., Gimeno, A., García‐Giménez, J. L., Pallardó, F. V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101424 · Cited by 29
Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age
Shaw, J., Marshall, T., Morris, H. G., Hayton, C., & Chaudhuri, N. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.111 · Cited by 29
Self-citationMortality from idiopathic pulmonary fibrosis: a temporal trend analysis in Brazil, 1979-2014
Algranti, E., Saito, C. A., Silva, D. R. M. E., Carneiro, A. P. S., & Bussacos, M. A. (2017) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562017000000035 · Cited by 22
Hammond, M., Clark, A., Cahn, A. P., Chilvers, E. R., Fraser, W. D., Livermore, D. M., Maher, T. M., Parfrey, H., Swart, A. M., Stirling, S., et al. (2018) · Trials · doi:10.1186/s13063-018-2453-6 · Cited by 19
Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
Hayton, C., & Chaudhuri, N. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0488-0 · Cited by 14
Self-citationGastroesophageal reflux and idiopathic pulmonary fibrosis: A long term relationship
Gnanapandithan, K., Popkin, J. H., Devadoss, R., & Martin, K. B. (2016) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2016.01.002 · Cited by 9
Towards a global initiative for fibrosis treatment (GIFT)
Molina‐Molina, M., Agustí, A. G. N., Crestani, B., Schwartz, D. A., Königshoff, M., Chambers, R. C., Maher, T. M., Faner, R., Mora, A. L., Rojas, M. M., et al. (2017) · ERJ Open Research · doi:10.1183/23120541.00106-2017 · Cited by 9
The Genetic Diagnosis of Interstitial Lung Disease: A Need for an International Consensus
Borie, R., Kannengiesser, C., Debray, M., & Crestani, B. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201611-2209le · Cited by 7
Cited by
Alveolar fibroblast lineage orchestrates lung inflammation and fibrosis
Tsukui, T., Wolters, P. J., & Sheppard, D. (2024) · Nature · doi:10.1038/s41586-024-07660-1 · Cited by 301
The Role of Macrophages in the Development of Acute and Chronic Inflammatory Lung Diseases
Lee, J.-W., Chun, W., Lee, H. J., Min, J.-H., Kim, S.-M., Seo, J.-Y., Ahn, K.-S., & Oh, S.-R. (2021) · Cells · doi:10.3390/cells10040897 · Cited by 291
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Self-citationValidation of the prognostic value of MMP‐7 in idiopathic pulmonary fibrosis
Tzouvelekis, A., Herazo‐Maya, J. D., Slade, M., Chu, J., Deiuliis, G., Ryu, C., Li, Q., Sakamoto, K., Ibarra, G., Pan, H., et al. (2017) · Respirology · doi:10.1111/resp.12920 · Cited by 130
Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review
Ranasinghe, P., Addison, M. L., Dear, J. W., & Webb, D. J. (2023) · British Journal of Pharmacology · doi:10.1111/bph.15972 · Cited by 138
Metadata
- Authors
- Barratt, S., Creamer, A., Hayton, C., & Chaudhuri, N.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2018-08-06
- Volume
- 7
- Issue
- 8
- Pages
- 201
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2885432230
- Cited by
- 382
- References
- 187
- FWCI
- 23.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.